Clinical Trials Logo

Lung Neoplasm clinical trials

View clinical trials related to Lung Neoplasm.

Filter by:

NCT ID: NCT03849040 Completed - Lung Diseases Clinical Trials

The Use of Artificial Intelligence to Predict Cancerous Lymph Nodes for Lung Cancer Staging During Ultrasound Imaging

Start date: April 8, 2019
Phase:
Study type: Observational [Patient Registry]

This study aims to determine if a deep neural artificial intelligence (AI) network (NeuralSeg) can learn how to assign the Canada Lymph Node Score to lymph nodes examined by endobronchial ultrasound transbronchial needle aspiration(EBUS-TBNA), using the technique of segmentation. Images will be created from 300 lymph nodes videos from a prospective library and will be used as a derivation set to develop the algorithm. An additional100 lymph node images will be prospectively collected to validate if NeuralSeg can correctly apply the score.

NCT ID: NCT03749512 Completed - Lung Neoplasm Clinical Trials

NLCR in Prediction of the Grade of Lung Tumor.

Start date: October 1, 2014
Phase:
Study type: Observational

The aim of the study is to assess whether the value of neutrophil-lymphocyte count ratio from the routine preoperative blood test may predict lung tumors' grading.

NCT ID: NCT03741868 Completed - Lung Neoplasm Clinical Trials

Symptom Burden and Unmet Supportive Care Needs in Lung Cancer Patients Undergoing First or Second Line Immunotherapy

Start date: October 16, 2016
Phase:
Study type: Observational

Doctors are recruiting patients receiving care for lung cancer at the Wake Forest Baptist Comprehensive Cancer Center asking about needs and experiences during immunotherapy. Immunotherapy is a new treatment for lung cancer. The research is to better understand patients' perspectives on what immunotherapy is like and will provide important information to help understand the symptoms patients experience, the impact of treatment on daily life, ways that people adapt to the challenges of treatment, and services that may help people live better during treatment.

NCT ID: NCT03658460 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer and Discovery of New Biomarkers

LimBio
Start date: August 22, 2018
Phase:
Study type: Observational

Lung cancer patients have a poor prognosis and only around 20 % is alive after 5 years. However, for advanced non-small cell lung cancer immunotherapy has become a cornerstone of treatment. Two immunotherapeutic drugs for lung cancer have been approved in the last two years. Immunotherapy blocks the capability of cancer cells to inactivate the patient´s immune system, thus re-enabling eradication of cancer cells. In clinical trials, immunotherapy has shown superior survival and less toxicity compared to standard chemotherapy. Whether the patients are candidates for immunotherapy or not is currently based on an unprecise biomarker that poorly predicts the patients who may benefit from immunotherapy. Immunotherapy can cause severe adverse effects and is expensive. Consequently, novel biomarkers are urgently needed from a patient perspective as well as a socioeconomic perspective. The objective of the project is to investigate changes in genes and other signals in tissue and blood samples from immunotherapy treated lung cancer patients. The investigators expect to identify new biomarkers that can predict with high precision, which patients may benefit from immunotherapy. On-treatment, the investigators also aim to identify biomarkers that predict the treatment response and reveal the underlying mechanisms when cancer cells become resistant to the treatment.

NCT ID: NCT03523689 Completed - Lung Neoplasm Clinical Trials

Radial-Probe Endobronchial Ultrasound in Detecting Atelectasis in Patients Undergoing Peripheral Bronchoscopy

Start date: April 30, 2018
Phase:
Study type: Observational

This trial studies how well radial-probe endobronchial ultrasound works in detecting the complete or partial collapse of the lung in patients undergoing peripheral bronchoscopy. Diagnostic procedures, such as radial-probe endobronchial ultrasound and bronchoscopy, use a thin, tube-like instrument inserted through the nose or mouth to view and take pictures of the inside of the trachea, air passages, and lungs.

NCT ID: NCT03516500 Completed - Lung Neoplasm Clinical Trials

Trial of Identifying the Lung Intersegmental Plane by Iron Sucrose Injection Staining

Start date: May 9, 2018
Phase: N/A
Study type: Interventional

This is a protocol to determine the safety and feasibility of using Iron Sucrose Injection to identify the intersegmental plane,not only on the pleural surface but also the parenchyma of the lung.

NCT ID: NCT03320044 Completed - Carcinoma Clinical Trials

Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing

Start date: October 18, 2017
Phase:
Study type: Observational

Analyse immune repertoire and genetic mutations of benign and malignant pulmonary noduleļ¼Œand evaluate peripheral blood detection for identifying nature of pulmonary nodule.

NCT ID: NCT03134729 Completed - Pain, Postoperative Clinical Trials

PATHOS Study Pain Assessment in Thoracic Oncologic Surgery

PATHOS
Start date: May 4, 2017
Phase: N/A
Study type: Interventional

A randomized prospective trial to assess whether the use of loco regional anesthesia as adjuvant analgesic therapy is more effective of intravenous analgesia only.

NCT ID: NCT03037385 Completed - Neoplasms Clinical Trials

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

ARROW
Start date: March 17, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.

NCT ID: NCT02966509 Completed - Prostate Cancer Clinical Trials

Engagement of Patients With Advanced Cancer

EPAC
Start date: August 2013
Phase: N/A
Study type: Interventional

The Engagement of Patients with Advanced Cancer is an intervention that utilizes well-trained lay health coaches to engage patients and their families in goals of care and shared decision-making after a diagnosis of advanced cancer. Although lay health workers have never been tested in this role, we hypothesize that lay health workers can feasibly improve goals of care documentation and help to reduce unwanted healthcare utilization at the end of life for Veterans diagnosed with new advanced stages of cancer and those diagnosed with recurrent disease.